• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    High Drug Loading Amorphous Solid Dispersions

    Parenteral Drug Delivery Trends

    Selecting the Right Outsourcing Model for Emerging Biotech

    Inhaled Drug Delivery Technology

    The Future of Biologics: Accelerating Production, Reducing Costs
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Altasciences Contributes to Vibegron Approval

    Cyprium, Sentynl Therapeutics Ink Asset Purchase Agreement

    Pfizer Selects Seven Bridges to Support RNA Sequencing Data

    ACG Launches ACG Laboratories

    Glatt and Aprecia Enter 3D-Printing Collaboration
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Why Increasing Solubility May Not Improve Bioavailability - In Vitro Predictions

    ACG Launches ACG Laboratories

    Glatt and Aprecia Enter 3D-Printing Collaboration

    Catalent Acquires Delphi Genetics

    Almac Group Completes $7M R&D Center
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Centrient Pharmaceuticals to Acquire Astral SteriTech

    Seasonal Vaccine Manufacturing

    PwC Joins Medicines Manufacturing Innovation Centre

    AARDEX Group Partners with Pill Connect

    Phillips-Medsize and Subcuject Collaborate
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Altasciences Contributes to Vibegron Approval

    Cyprium, Sentynl Therapeutics Ink Asset Purchase Agreement

    Why Increasing Solubility May Not Improve Bioavailability - In Vitro Predictions

    Pfizer Selects Seven Bridges to Support RNA Sequencing Data

    ACG Launches ACG Laboratories
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Top BioPharma Form Accumulus Synergy

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Emergent BioSolutions

    Baxter BioPharma Solutions

    Almac Group

    Reed-Lane

    Adare Pharma Solutions
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    PCI Pharma Services

    Adare Pharma Solutions

    Almac Group

    Syngene

    test company saurabh
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    High Drug Loading Amorphous Solid Dispersions

    A Novel Tablet Architecture for Amorphous Solid Dispersions to Achieve High Drug Loadings

    High Drug Loading Amorphous Solid Dispersions
    High Drug Loading Amorphous Solid Dispersions
    Figure 1. Dry Tg versus drug loading for erlotinib (top) and posaconazole (bottom) ASDs using either Eudragit L100 or HPMCAS-H as the dispersion polymer.1,2
    High Drug Loading Amorphous Solid Dispersions
    Figure 2. In vitro CTD performance of erlotinib tablets at a 100-mg active dose.1,11
    High Drug Loading Amorphous Solid Dispersions
    Figure 3. In vitro CTD performance of posaconazole tablets at a 100-mg active dose.2
    High Drug Loading Amorphous Solid Dispersions
    Figure 4. Blood-plasma concentration profiles for posaconazole. Data plotted are the mean blood-plasma concentrations with a single standard deviation.2,12
    High Drug Loading Amorphous Solid Dispersions
    Figure 5. Box-and-whisker plots showing AUC values in beagle dogs for posaconazole formulations.
    High Drug Loading Amorphous Solid Dispersions
    Table 1. Posaconazole and erlotinib tablet formulations (100-mg active dose).1,2
    High Drug Loading Amorphous Solid Dispersions
    Table 2. ASD physical stability after storage at accelerated conditions.1,2
    Deanna Mudie and Aaron Stewart, Lonza 01.27.21
    Amorphous solid dispersions (ASDs) can increase the bioavailability of poorly water-soluble drugs by increasing dissolved drug concentrations in the gastrointestinal (GI) tract. However, ASD dosage forms are often large or require multiple tablets or capsules to meet dose requirements, decreasing patient compliance, particularly among pediatric or geriatric patients who may have difficulty swallowing.

    To address this challenge, a high-loaded dosage form (HLDF) architecture for ASDs was developed that strategically combines two different polymers—one “inside” and one “outside” the ASD—to maximize bioperformance, physical stability, and drug loading. The HLDF approach differs from traditional ASD architectures in which a single polymer “inside” the ASD must play dual roles—maximizing bioperformance and physical stability. This constrains the formulation by relying on a single type and amount of polymer, and often results in a dosage form with low drug loading. The HLDF architecture can reduce tablet mass by at least 40% compared to a traditional ASD tablet, with similar or better physical stability and performance.

    This article describes the HLDF formulation architecture and presents results for HLDF formulations based on two model drugs (erlotinib and posaconazole), describing in vitro and in vivo performance, physical stability, and manufacturability. Compared to traditional ASD formulations, the HLDF formulations had equivalent physical stability and in vitro performance, with a 40% reduction in tablet mass. Further, posaconazole HLDF tablets achieved equivalent in vivo performance to benchmark tablets and erlotinib HLDF tablets demonstrated excellent kilogram scale manufacturability.*1,2

    Formulation Architecture
    HLDF Formulation Concept
    The HLDF architecture is designed to minimize the mass of the dosage form and/or the number of dosage-form units (e.g., tablets or capsules) required to achieve the desired dose, while still maintaining good physical stability, performance, and manufacturability. The dosage form mass and/or number of dosage-form units—known as the dosage-form burden—can be minimized by maximizing the drug loading in the ASD and the ASD loading in the dosage form.

    In formulating an HLDF, two key factors must be considered: 1) maintaining physical stability and 2) providing the desired bioperformance. To achieve good physical stability at high drug loadings, it is helpful to select a dispersion polymer with a high glass-transition temperature (Tg) to help kinetically trap the drug in the amorphous state.3 The enteric polymer Eudragit L100—poly(methyl methacrylate-co-methacrylic acid) [PMMA] (1:1) (Evonik Industries, Essen, Germany) has proven to be a good choice. Its high Tg is 30°C to 70°C higher than other common dispersion polymers such as hydroxypropyl methyl cellulose acetate succinate (HPMCAS), hydroxypropyl methylcellulose (HPMC), polyvinylpyrrolidone (PVP), and polyvinylpyrrolidone vinyl acetate (PVP VA).4
    However, Eudragit L100 is typically less effective at sustaining supersaturated drug concentrations in GI fluids compared to polymers such as HPMCAS.5,6,7 HPMCAS is a particularly effective concentration-sustaining polymer (CSP) due its amphiphilic nature when ionized at the pH of the small intestine.8

    The HLDF approach capitalizes on the advantages of both types of polymers, leveraging Eudragit L100’s ability to maintain physical stability at high drug loadings without sacrificing supersaturation sustainment in GI fluids. In the HLDF approach, a CSP such as HPMCAS is included “outside” the ASD by granulating it with the ASD and typical tableting excipients. Strategically combining two different polymers, one “inside” and one “outside” the ASD, removes the constraint of the traditional ASD approach, in which a single dispersion polymer must maintain physical stability and sustain supersaturation in solution. Because higher drug loadings can be achieved with this architecture, the HLDF approach enables an overall increase in drug loading within the dosage form and decreases the dosage-form burden.

    Results for Two HLDF Formulations
    Posaconazole and Erlotinib Tablet Formulations
    In this study, we investigated three different types of tablet formulations using two model compounds, posaconazole and erlotinib. The formulations, shown in Table 1, were (1) HLDF tablets using Eudragit L100 as the dispersion polymer and external HPMCAS as the CSP; (2) traditional ASD tablets (labeled “benchmark” tablets) using HPMCAS as both the dispersion polymer and the CSP; and (3) negative-control tablets using Eudragit L100 as the dispersion polymer, but without a CSP.

    In the case of posaconazole, the 250-mg HLDF tablet had a 40% smaller mass compared to the benchmark tablet.2 For erlotinib, the 350-mg HLDF tablet had a 40% smaller mass compared to the benchmark tablet.1 For both model drugs, the negative-control tablet was designed to have a mass similar to that of the HLDF tablet.

    For each formulation, drug loading in the ASD was maximized by choosing the highest drug loading that produced an ASD that was physically stable after storage for four weeks at accelerated temperature and relative humidity (RH), as described below. The ASD loading in the tablet was maximized while still achieving rapid disintegration (i.e., < 3 min) and dissolution rate, and facilitating good downstream manufacturability.

    Physical Stability
    To maintain good physical stability, an ASD must remain homogenous and amorphous, without exhibiting changes in particle morphology (such as particle fusing) during its shelf life. For most spray-dried ASDs, the concentration of drug in the ASD exceeds the crystalline solubility of the drug in the polymer, leading to a thermodynamic driving force for crystallization. To facilitate good physical stability over the shelf life of an ASD drug product, the goal is to create a homogeneous ASD that is kinetically stabilized at relevant storage temperatures.

    The Tg of the ASD is a key factor driving kinetic stabilization. When the ASD Tg is sufficiently higher than the storage temperature, molecular mobility can be low enough to limit drug diffusion, which is a precursor to crystallization.9,10 Since the drug Tg is usually much lower than the polymer Tg, increasing the drug loading in the ASD typically decreases the ASD Tg. In addition, it is generally true that the higher the polymer Tg, the higher the ASD Tg at a given drug loading. As shown in Figure 1, using Eudragit L100 (Tg = 187°C) versus HPMCAS-H (Tg = 119°C) as the dispersion polymer significantly increased ASD Tg at a given loading of erlotinib or posaconazole.

    The physical stability of ASDs can be assessed by conducting aging studies at accelerated temperature and RH since these conditions tend to accelerate molecular mobility. Eudragit L100 and HPMCAS-H ASDs made with erlotinib or posaconazole at different drug loadings were stored at elevated temperature and RH for four weeks and assessed for amorphous content, morphology, and Tg.

    Good ASD stability was indicated by (1) lack of sharp diffraction peaks in a powder x-ray diffraction (PXRD) diffractogram, (2) lack of fusing and morphology changes in scanning electron microscopy (SEM) micrographs and (3) a single Tg without melting events in the modulated differential scanning calorimetry (mDSC) thermogram. As shown in Table 2, Eudragit L100 gave stable drug loadings that were 1.9-fold higher for erlotinib ASDs and 1.5-fold higher for posaconazole ASDs.1,2 These results highlight the advantage in selecting Eudragit L100 rather than HPMCAS as the dispersion polymer when a high drug loading is desired.

    In Vitro Dissolution
    A controlled-transfer dissolution (CTD) test was used to evaluate in vitro dissolution of erlotinib and posaconazole tablets. In this test, a dosage form is introduced to a compartment with simulated gastric fluid (HCl, pH 2) and transits into a compartment with simulated duodenal fluid (67 mM phosphate buffer and 6.7 mM fasted-state simulated intestinal fluid [FaSSIF] powder, pH 6.5) at a monoexponential rate with a half-life of emptying of 15 minutes.

    Drug dissolution profiles from the CTD test are shown in Figure 2 for erlotinib and Figure 3 for posaconazole tablets, respectively. For both drugs, the performance of the HLDF tablet and benchmark tablet was similar.1,2 Similar concentration sustainment was observed despite the HLDF tablet containing a lower ratio of CSP to drug than the benchmark tablet. In contrast, the performance of the negative-control tablet, which did not contain a CSP, was worse, due to more rapid crystallization of drug in the duodenum compartment.

    In Vivo Testing
    To determine whether incorporating a CSP “outside” the ASD would be as effective as the benchmark approach in which the CSP is “inside” the ASD, an in vivo study was conducted in fasted beagle dogs using the model drug posaconazole.2 A 100-mg dose (10 mg/kg) of posaconazole was administered using the HLDF tablets, benchmark tablets, negative-control tablets, and a commercial crystalline oral suspension (Noxafil OS). Dogs were pretreated with an intramuscular injection of pentagastrin (6 μg/kg, 60 μg/ml, 0.1 ml/kg) approximately 30 minutes before dose administration to increase gastric acid secretion and lower stomach pH.

    The average blood-plasma concentration profiles for each formulation are shown in Figure 4. Box-and-whisker plots, comparing the area under the curve (AUC) of the plasma concentration-time profiles generated using noncompartmental analysis, are shown in Figure 5. The HLDF tablet showed equivalent AUC values compared to the benchmark tablet, demonstrating that incorporating the CSP “outside” the ASD was as effective as including it “inside” the ASD. In addition, the HLDF tablet showed the least variability in AUC of all formulations. For instance, the percent coefficient of variation (%CV) for the AUC was two-fold less for the HLDF tablet than for the negative-control tablet and Noxafil OS. Only the HLDF tablets had a statistically significant difference in AUC compared to Noxafil OS (p values < 0.05), with an average two-fold improvement.

    Kilogram-Scale Manufacturability
    To demonstrate the feasibility of making tablets at a kilogram scale using an excipient with a fine particle size (i.e., HPMCAS-HF) external to the ASD, erlotinib HLDF tablets were manufactured using a 5-kg pregranulation blend.1 Granulation was performed on a Gerteis Mini-Pactor roller compactor and tableted on a Korsch XL 100 rotary tablet press.

    The quality attributes of the HLDF tablets produced using this process were excellent, with rapid disintegration, low friability, and high content uniformity. Compressibility, tabletability, and compactibility (CTC) profiles generated on the final blend at 100 msec and 10 msec using an MCC Presster compaction emulator suggested good tableting performance at clinical- and commercial-scale dwell times.

    Conclusions
    The HLDF approach can reduce tablet mass by at least 40% with similar or better physical stability and in vitro performance compared to a traditional ASD tablet. This result was demonstrated using the model drugs erlotinib and posaconazole. A study in dogs using posaconazole HLDF tablets showed equivalent in vivo performance to traditional ASD tablets. Kilogram-scale spray drying and tableting of the erlotinib HLDF formulation demonstrated excellent manufacturability. The HLDF approach can reduce tablet burden while achieving good performance, stability, and manufacturability for ASD drug products. As pharma and biotech innovators continue to advance bioavailability-challenged molecules to clinic and to market, ASD production methods that allow for high drug loadings may be beneficial. 

    Note: All Figures and Tables appear in the slider image box at the top of the article.

    References
    1. Mudie DM, Buchanan S, Stewart AM, Smith A, Shepard KB, Biswas N, Marshall D, Ekdahl A, Pluntze A, Craig CD, Morgen MM, Baumann JM, Vodak DT. “A novel architecture for achieving high drug loading in amorphous spray dried dispersion tablets,” Int J Pharm X. (2020) Feb 19;2:100042.
    2. Mudie DM, Stewart AM, Biswas N, Brodeur TJ, Shepard KB, Smith A, Morgen MM, Baumann JM, Vodak DT. “Novel High-Drug-Loaded Amorphous Dispersion Tablets of Posaconazole; In Vivo and In Vitro Assessment,” Mol Pharm. (2020) Sep 4.
    3. Babcock, W., J. Nightingale R. Shankar, “Pharmaceutical Solid Dispersions,” U.S. Patent No. 8,481,081 B2, Bend Research, Inc., USA (2013).
    4. Shepard, K.B., M.S. Adam, M.M. Morgen, D.M. Mudie, D.T. Regan, J.M. Baumann, D.T. Vodak. “Impact of Process Parameters on Particle Morphology and Filament Formation in Spray Dried Eudragit L100 Polymer,” Powder Technol., 362 (2020) 221-230.
    5. Mosquera-Giraldo, L.I., C.H. Borca, X. Meng, K.J. Edgar, L.V. Slipchenko, L.S. Taylor, “Mechanistic Design of Chemically Diverse Polymers With Applications in Oral Drug Delivery,” Biomacromolecules, 17(2016)3659-3671.
    6. Ilevbare, G.A., H. Liu, K.J. Edgar, L.S. Taylor, “Maintaining Supersaturation in Aqueous Drug Solutions: Impact of Different Polymers on Induction Times,” Cryst. Growth Des., 13 (2013)740-751.
    7. Price, D.J., F. Ditzinger, N.J. Koehl, S. Jankovic, G. Tsakiridou, A. Nair, R. Holm, M. Kuentz, J.B. Dressman, C. Saal, “Approaches To Increase Mechanistic Understanding and Aid in the Selection of Precipitation Inhibitors for Supersaturating Formulations – A PEARRL Review,” J. Pharm. Pharmacol., 71 (2019) 483-509.
    8. Friesen, D.T., R. Shanker, M. Crew, D.T. Smithey, W.J. Curatolo, J.A.S. Nightingale, “Hydroxypropyl Methylcellulose Acetate Succinate-Based Spray-Dried Dispersions: An Overview,” Mol. Pharm., 5(2008)1003-1019.
    9. Vig, B., M. Morgen, “Formulation, Process Development, and Scale-Up: Spray-Drying Amorphous Solid Dispersions for Insoluble Drugs,” Chapter 30 in Developing Solid Oral Dosage Forms, Second Edition, Y. Qiu, Y. Chen, G.G.Z. Zhang, L. Yu, R.V. Mantri (eds.). Academic Press, Boston (2017), pp. 793-82.
    10. Yang, J., K. Grey, J. Doney, “An Improved Kinetics Approach To Describe the Physical Stability of Amorphous Solid Dispersions,” Int. J. Pharm., 384 (2010) 24-31.
    11. https://doi.org/10.1016/j.ijpx.2020.100042
    12. https://pubs.acs.org/doi/abs/10.1021/acs.molpharmaceut.0c00471.
        Further permissions related to the material excerpted should be directed to the ACS

    Related Features

    • Parenterals
      Parenteral Drug Delivery Trends

      Parenteral Drug Delivery Trends

      A Q&A with Lubrizol Life Science Health’s CDMO Division President, Rob Lee.
      Kristin Brooks, Managing Editor, Contract Pharma 01.27.21

    • Selecting the Right Outsourcing Model for Emerging Biotech

      Selecting the Right Outsourcing Model for Emerging Biotech

      Flexible outsourcing models help drive quality, control costs and enable better efficiencies and faster delivery.
      Timothy King and Elisha Talley-Roithner, PPD 01.27.21

    • Drug Delivery
      Inhaled Drug Delivery Technology

      Inhaled Drug Delivery Technology

      The success of any new inhaled medicine relies in a large part on the correct combination of formulation and device technology being chosen for its delivery.
      Dr. Sandy Munro, Vice President – Pharmaceutical Development, Vectura 01.27.21


    • Biologics, Proteins, Vaccines
      The Future of Biologics: Accelerating Production, Reducing Costs

      The Future of Biologics: Accelerating Production, Reducing Costs

      Yeast-based gene expression offers pharma the yield and efficiencies it needs to make pandemic-stopping vaccines faster and more economical.
      Mark Emalfarb, Dyadic 01.27.21

    • Analytical Services | Information Technology | Laboratory Testing
      Business Intelligence For (and From) the Lab

      Business Intelligence For (and From) the Lab

      How a digital ecosystem can harness the most data-rich environment in the CDMO.
      Bob Voelkner, VP Sales and Marketing, LabVantage 01.27.21

    • Communicating Your Contracting Priorities to Your Drug Company Customers

      Communicating Your Contracting Priorities to Your Drug Company Customers

      A discussion with Perrigo’s senior legal counsel, Susan Fyan, about issues that arise in very fact-specific contract negotiations between CDMOs and sponsors.
      Stephen Sayre, Dykema 01.27.21


    • COVID-19 Impact Report

      COVID-19 Impact Report

      Leaders across the pharmaceutical contract services industry reflect on the impact of COVID-19 in 2020, and what to expect in 2021.
      Tim Wright, Editor, Contract Pharma 01.27.21

    • Biologics, Proteins, Vaccines | Regulatory Affairs
      The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

      The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

      A look at EUA standards and approvals, unavoidable pitfalls, Operation Warp Speed, FDA’s use of Real-World Evidence, and a slow return to “normalcy.”
      Chad Landmon, Michelle Divelbiss and Alex Alfano, Attorneys - Axinn, Veltrop & Harkrider LLP 01.27.21

    • Excipients
      Bye-Bye China?

      Bye-Bye China?

      Instead of closing its doors on China, Western pharma industry needs to take a balanced approach and perform proper due diligence based on objective criteria.
      Michele Jermini and Enrico Polastro 11.17.20


    • Clinical Trials | Information Technology | R&D
      Decentralized Trials Fuel AI Revolution in Clinical Research

      Decentralized Trials Fuel AI Revolution in Clinical Research

      The life sciences industry is giving clinical a full makeover, dramatically improving how new therapeutics are developed.
      Nick Moss, Vice President of Analytics and Machine Learning, Medable 11.17.20

    • Drug Delivery | Injectables
      Self-Medication: Flexibility for Patients and Drug Manufacturers

      Self-Medication: Flexibility for Patients and Drug Manufacturers

      Bringing together self-medication with auto-injectors and sustainable secondary packaging.
      Matthias Heinrichs, Head of Product Management and Project Engineering, Syntegon Technology 11.17.20

    • The Single-Use Mixing Landscape: Evaluating Your Options

      The Single-Use Mixing Landscape: Evaluating Your Options

      Adoption of single-use technologies has increased markedly in recent years and will continue to grow.
      Mark A. Sitcoske, Founder & CEO, High Purity New England 11.17.20


    • DCAT President Talks COVID-19, Drug Manufacturing and Innovation

      DCAT President Talks COVID-19, Drug Manufacturing and Innovation

      Lonza’s Director of Commercial Development, Sean Diver, was recently named President of DCAT.
      Tim Wright, Editor, Contract Pharma 11.17.20

    • Biologics, Proteins, Vaccines | Biosimilars | Drug Development
      Biopharma Contract Manufacturing: Robust Growth Ahead

      Biopharma Contract Manufacturing: Robust Growth Ahead

      The biopharmaceutical contract manufacturing market is projected to reach $6.3 billion in 2020, and it will continue to grow over the next five years.
      William Downey, HighTech Business Decisions 11.17.20

    • Injectables
      Catering for the Complex

      Catering for the Complex

      The rapidly changing landscape of pharmaceutical packaging.
      Marcelo Cruz, Director Business Development and Marketing, Tjoapack 11.17.20

    Trending
    • Catalent Acquires Delphi Genetics
    • Inside A Vaccine Trial
    • Wavelength Pharmaceuticals Acquires Majority Stake In Vanamali Organics
    • Century Therapeutics Significantly Expands Capabilities
    • ICON Acquires Medpass
    Breaking News
    • Altasciences Contributes to Vibegron Approval
    • Cyprium, Sentynl Therapeutics Ink Asset Purchase Agreement
    • Pfizer Selects Seven Bridges to Support RNA Sequencing Data
    • ACG Launches ACG Laboratories
    • Glatt and Aprecia Enter 3D-Printing Collaboration
    View Breaking News >
    CURRENT ISSUE

    January/February 2021

    • High Drug Loading Amorphous Solid Dispersions
    • Parenteral Drug Delivery Trends
    • Selecting the Right Outsourcing Model for Emerging Biotech
    • Inhaled Drug Delivery Technology
    • The Future of Biologics: Accelerating Production, Reducing Costs
    • Business Intelligence For (and From) the Lab
    • Communicating Your Contracting Priorities to Your Drug Company Customers
    • COVID-19 Impact Report
    • The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Clinical Trial Finds Metabolic Benefits for Polyphenols Formula
    JRF Technology Debuts Elderberry Oral Film Strip
    Danone Adds to Plant-Based Portfolio with Acquisition of Follow Your Heart Brand
    Coatings World

    Latest Breaking News From Coatings World

    Hempel Launches Sustainability Framework: Futureproof
    ChemQuest Hires Rich Gibson
    New Increase in Kynar Fluoropolymer Capacities at Arkema's Chinese Site
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Terumo to Purchase Predictive Analytics Firm Health Outcomes Sciences
    Abiomed Leader Michael Minogue Named AdvaMed Board Chairman
    TransEnterix Changes Name to Asensus Surgical
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Altasciences Contributes to Vibegron Approval
    Cyprium, Sentynl Therapeutics Ink Asset Purchase Agreement
    Pfizer Selects Seven Bridges to Support RNA Sequencing Data
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Madison Reed Raises $52 Million in Financing Round
    The Estée Lauder Companies Closes Becca Cosmetics
    Afro Sheen Launches New Brand Initiatives
    Happi

    Latest Breaking News From Happi

    PBA Opposes House Bill 2325 in West Virginia
    J.R. Watkins Tackles Pain with New Lines
    RB Launches Vanish Miracle
    Ink World

    Latest Breaking News From Ink World

    Etiflex Enters New Markets with Nilpeter FA-22 Installation
    Hydrocarbon Solvents Market to Surpass $8.1 Billion by 2030
    Lowe-Martin Adds 2 KODAK NEXFINITY Digital Presses
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Eaglewood Technologies debuts new anilox cleaning system
    INX International and VerifyMe sign supply agreement
    Soma partners with DTM Flexo Services
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    H&V Announces Price Increase
    Fiber Bond VE3 Technology Inactivates SARS-CoV-2 in HVAC Filtration Systems
    Citizens Provides $325 Million Senior Credit Facility to Nice-Pak
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    NuVasive Nabs Simplify Medical for $150M
    SeaSpine Begins Limited Launch of WaveForm TA (TLIF Articulating) 3D-Printed Interbody
    Nexus Spine Implants for Use in Spinal Surgeries Become Available
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Comercial Kywi Improves Customer Service, Front-Store Operations with Zebra Mobile Solution
    Global Printed Circuit Board Market Projected to Reach $69.32 Billion by 2027
    RFID Locks Market to Reach $9.93 Billion by 2027: Allied Market Research

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login